Helix retains ~$120M trust (60%+) after redemptions; PIPE adds ~$261M for BBOT deal

BridgeBio Oncology Therapeutics, Inc.

Retained ~$120M in trust (~60%+ of original) after redemptions; 2nd lowest biotech de-SPAC redemption rate since 2022.
Total expected gross proceeds ~$382M including ~$261M from PIPE led by Cormorant Asset Management and other investors.
Business combination with BridgeBio Oncology Therapeutics (BBOT) expected to close expeditiously, subject to conditions.
Redemption request deadline was July 31, 2025; the low redemption rate signals shareholder support for the deal.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.